Palmatine blocks GAPDH K263 lactylation, thereby inhibiting glycolysis and osteogenic differentiation in calcific aortic valve disease
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Qianqian Du und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China. Hauptthemen laut MEDLINE: Glycolysis, Osteogenesis, Calcinosis, Cell Differentiation. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Science and Technology Major Project, Science and Technology Program of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Calcific aortic valve disease (CAVD) is a prevalent cardiovascular disorder for which no effective pharmacotherapy has been approved. This study aims to investigate the therapeutic potential of palmatine (PAL) in CAVD and to elucidate the underlying molecular mechanism, with a focus on its role in metabolic-epigenetic crosstalk. The anti-calcification effect of PAL was evaluated in human aortic valve interstitial cells (hVICs) using qRT-PCR, Western blotting, and Alizarin Red S staining. Integrated multi-omics profiling (transcriptomics and metabolomics) together with lactylomics revealed that PAL primarily interferes with glycolytic metabolism and global lysine lactylation levels. The interaction between PAL and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was assessed via molecular docking and surface plasmon resonance (SPR). The functional significance of GAPDH K263 lactylation (K263lac) was investigated using site-specific mutagenesis. PAL treatment significantly inhibited osteogenic differentiation and calcification of hVICs. Mechanistically, PAL directly bound to GAPDH, selectively reducing its lactylation at the K263 residue. Mutating K263 to arginine (K263R) mimicked the effect of PAL, abrogating the PAL-mediated suppression of glycolysis, osteogenic gene expression, and calcium deposition. Immunofluorescence analysis further confirmed that PAL treatment markedly reduced cytoplasmic K263lac levels, and the K263R mutation completely abolished this modification. In vivo, PAL administration in a high-fat diet-fed ApoE-/- mouse model significantly alleviated aortic valve calcification, as evidenced by echocardiography and von Kossa staining. In conclusion, GAPDH K263lac represents a novel druggable target in CAVD. By directly targeting this modification, palmatine disrupts glycolysis and osteogenic differentiation, highlighting its therapeutic potential for CAVD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
- School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Shizhen Laboratory, Wuhan 430065, China.
- School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; Ningbo Rehabilitation Hospital, Wenzhou Medical University, Ningbo 315040, China.
- School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China.
- School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Shizhen Laboratory, Wuhan 430065, China.
- Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Engineering Research Center of Antitumor Natural Drugs, Natural Drug Intervention in Aging…
Förderung
- National Science and Technology Major Project
- Science and Technology Program of Hubei Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Du, Q., Wu, J., Wang, S., Wang, S., Yu, H., Liu, M., Hou, S., Jiang, S., Xu, H., Ye, S., Lu, Y., Chen, L., Li, A., Feng, F., Pang, Y., Pan, L., Wang, C., & Xu, K. (2026). Palmatine blocks GAPDH K263 lactylation, thereby inhibiting glycolysis and osteogenic differentiation in calcific aortic valve disease. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118449
Vancouver
Du Q, Wu J, Wang S, Wang S, Yu H, Liu M, et al. Palmatine blocks GAPDH K263 lactylation, thereby inhibiting glycolysis and osteogenic differentiation in calcific aortic valve disease. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118449
BibTeX
@article{Du2026,
author = {Du, Qianqian and Wu, Jiaqin and Wang, Shunshun and Wang, Sixiang and Yu, Huiming and Liu, Minfu and Hou, Shuwan and Jiang, Shan and Xu, Huajiao and Ye, Siyi and Lu, Yihong and Chen, Lin and Li, Anzheng and Feng, Fan and Pang, Yi and Pan, Lianhong and Wang, Chunli and Xu, Kang},
title = {Palmatine blocks GAPDH K263 lactylation, thereby inhibiting glycolysis and osteogenic differentiation in calcific aortic valve disease},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118449}
}
EUVIMED